A Phase I randomized blinded single dose comparison of the safety pharmacokinetics and pharmacodynamics of SYN008 and omalizumab (Xolair) in healthy adult subjects
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma; Urticaria
- Focus Adverse reactions
- 11 Jan 2017 Status changed from not yet recruiting to completed.
- 01 Jul 2016 New trial record